Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.47

+0.3%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9080)	9/9/2003 5:46:41 PM
From: Icebrg	Read Replies (1) of 52153

Peter >>You seen anything about which one of Preos or Forteo might have an edge in efficacy? >> No, there is nothing available as far as I know. I guess that NPSP prefers to keep quiet about this for both regulatory and competitive reasons. >>Forteo is just a fragment of Preos, right?>> Yes >>I suppose there is still some chance that Preos won't have the rat tox problem (osteosarcoma) that Forteo showed - if so then it would be a big winner.>> That possibility was mentioned by NPSP today. That would of cause be a very big advantage. Another potential advantage could be if NPSP are allowed to market the drug directly to "consumers". Lilly may not do that with Forteo. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next